Advanced search
Publication Cover
Patient Preference and Adherence Volume 11, 2017 - Issue
Submit an article Journal homepage
60
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data

Kamal Hamed1 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USACorrespondence[email protected]
,
Valentino Conti2 Novartis Global Service Center, Dublin, Ireland
,
Hengfeng Tian1 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
&
Emil Loefroth3 Novartis Sverige AB, Täby, Sweden
Pages 831-838 | Published online: 27 Apr 2017

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Anne Haaije de Boer, Paul Hagedoorn & Floris Grasmeijer. (2022) Dry powder inhalation, part 2: the present and future. Expert Opinion on Drug Delivery 19:9, pages 1045-1059.
Read now
Stanley B. Fiel & Erica A. Roesch. (2022) The use of tobramycin for Pseudomonas aeruginosa: a review. Expert Review of Respiratory Medicine 16:5, pages 503-509.
Read now

Articles from other publishers (8)

Jessica WilliamsJames SeverinBen TempertonPhilip J. Mitchelmore. (2023) Phage Therapy Administration Route, Regimen, and Need for Supplementary Antibiotics in Patients with Chronic Suppurative Lung Disease. PHAGE 4:1, pages 4-10.
Crossref
Aaron C Miller, Logan M Harris, Joseph E Cavanaugh, Mahmoud Abou Alaiwa, David A Stoltz, Douglas B Hornick & Philip M Polgreen. (2022) The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor. Clinical Infectious Diseases 75:7, pages 1115-1122.
Crossref
Michael R. Loebinger, Eva Polverino, James D. Chalmers, Harm A.W.M. Tiddens, Herman Goossens, Michael Tunney, Felix C. Ringshausen, Adam T. Hill, Rashidkhan Pathan, Gerhild Angyalosi, Francesco Blasi, Stuart J. Elborn & Charles S. Haworth. (2021) Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa- infected bronchiectasis patients: iBEST study . European Respiratory Journal 57:1, pages 2001451.
Crossref
Anne Haaije de Boer & Kyrre Thalberg. 2021. Inhaled Medicines. Inhaled Medicines 99 146 .
Luis Máiz Carro & Marina Blanco-Aparicio. (2020) Nuevos antibióticos inhalados y formas de administración. Open Respiratory Archives 2:3, pages 251-264.
Crossref
Marsha Tan, Felisa Reyes-Ortega & Elena K. Schneider-Futschik. (2020) Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis. Magnetochemistry 6:2, pages 25.
Crossref
Cecilia Velino, Francesca Carella, Alessio Adamiano, Maurizio Sanguinetti, Alberto Vitali, Daniele Catalucci, Francesca Bugli & Michele Iafisco. (2019) Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis. Frontiers in Bioengineering and Biotechnology 7.
Crossref
Jeffry Weers. (2019) Comparison of Phospholipid-Based Particles for Sustained Release of Ciprofloxacin Following Pulmonary Administration to Bronchiectasis Patients. Pulmonary Therapy 5:2, pages 127-150.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.